January
SeSeRaKaJuSaMi
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
February
SeSeRaKaJuSaMi
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
March
SeSeRaKaJuSaMi
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
April
SeSeRaKaJuSaMi
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
May
SeSeRaKaJuSaMi
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
June
SeSeRaKaJuSaMi
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
July
SeSeRaKaJuSaMi
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
August
SeSeRaKaJuSaMi
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
September
SeSeRaKaJuSaMi
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
October
SeSeRaKaJuSaMi
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
November
SeSeRaKaJuSaMi
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
December
SeSeRaKaJuSaMi
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Kepadatan peristiwa:
1-5
6-9
10-12
13+
Peristiwa di 2004
—
2004: Bevacizumab: First Anti-Angiogenic Cancer Drug (2004)
Landmark Approval
Bevacizumab validated Judah Folkman's angiogenesis hypothesis after three decades of controversy and launched the anti-VEGF drug class. It established tumour …
—
2004: Rofecoxib (Vioxx) Cardiovascular Risk Withdrawal (2004)
Drug Withdrawal
The rofecoxib withdrawal reshaped [[term:pharmacovigilance|pharmacovigilance]] globally, prompting mandatory post-marketing commitments, expanded use of FDA's Sentinel System for real-world safety monitoring, …